Stock Monitor: BioPharmX Post Earnings Reporting
LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=MBVX as the Company's latest news hit the wire. On December 13, 2017, the Company, which is a clinical-stage biotechnology organization that works towards the development of antibody-based products to address unmet medical needs in the treatment of cancer, declared that it has concluded the enrollment and dosing of all patients in the initial cohort of the Phase-1 clinical trial for assessing the safety and efficacy of MVT-1075 for the treatment of pancreatic, colon, and lung cancer. Sign up now for our free research reports at:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for BioPharmX Corporation (NYSE AMER: BPMX), which also belongs to the Healthcare sector as the Company MabVax Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=BPMX
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, MabVax Therapeutics Holdings most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:
www.active-investors.com/registration-sg/?symbol=MBVX
Treating Cancer Using MVT-1075
- MVT-1075 is MabVax's new human antibody-based radio immunotherapy (RIT) product that combines the established clinical efficacy of radiation therapy with tumor specific targeting.
- It has the capability to deliver a more potent HuMab-5B1 based product. MVT-1075 uses small doses of the Company's MVT-5873 antibody, in combination with a radioisotope to target pancreatic cancer cells and kill them.
- It uses the commercially-validated radionuclide, 177Lutetium, for producing a lethal dose of radiation for the targeted cancer cells.
Phase-1 Trial Data Expected in Q1 2018
- The Phase-1 trial is a first-in-human clinical trial for MVT-1075. It is an open-label, multi-center study that intends to evaluate the safety and efficacy of MVT-1075 in 22 patients who have noted CA19-9 positive malignancies in the US.
- This dose-escalation study is based on the traditional 3+3 design.
- The primary endpoint is to compute the maximum tolerated dose and safety profile in patients who have recurring disease with failed prior therapies. And the secondary endpoints include the evaluation of tumor response rates and the duration of response by RECIST 1.1, the assessment of dosimetry, and pharmacokinetics.
- The investigative sites for this trial comprise Honor Health in Scottsdale, Arizona and Memorial Sloan Kettering Cancer Center in New York City.
- MabVax intends to report interim results from the Phase-1 trial early in the first quarter of 2018. Besides, it also plans to continue the dose escalation phase of the program.
Data Substantiates Safety and Efficacy of MVT-1075
MabVax has previously shared data that substantiates the efficacy of its radio immunotherapy product MVT-1075. The Company shared pre-clinical results for MVT-1075 at the American Association of Clinical Research (AACR) Annual Meeting in April 2017. As per the data, MVT-1075 exhibited marked suppression, and in some instances, regression of tumor growth in xenograft animal models of pancreatic cancer. This implies that MVT-1075 could prove to be an important new therapeutic agent in the treatment of pancreatic, colon, and lung cancers.
Moreover, MVT-1075 RIT clinical investigation data was also supported by MabVax's successful Phase-1a safety and target specificity data that was reported at the annual meetings of the American Society for Clinical Oncology (ASCO) and the Society for Nuclear Medicine and Molecular Imaging (SNMMI), including the clinical results for the Company's single agent therapeutic antibody MVT-5873 and immuno-PET imaging agent MVT-2163. The combined results from 50 patients in the Phase-1a MVT-5873 and MVT-2163 studies validated safety and provided insight into drug bio distribution and an optimal dosing strategy, which the Company incorporated into its MVT-1075 program.
Stock Performance Snapshot
December 14, 2017 - At Thursday's closing bell, MabVax Therapeutics Holdings' stock declined 4.59%, ending the trading session at $0.81.
Volume traded for the day: 149.63 thousand shares.
Stock performance in the last month – up 24.62%; and previous three-month period – up 15.71%
After yesterday's close, MabVax Therapeutics Holdings' market cap was at $14.55 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
